Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Clin Pharmacol Ther
2009 Feb 01;852:155-63. doi: 10.1038/clpt.2008.95.
Show Gene links
Show Anatomy links
Pharmacogenetic pathway analysis of docetaxel elimination.
Baker SD
,
Verweij J
,
Cusatis GA
,
van Schaik RH
,
Marsh S
,
Orwick SJ
,
Franke RM
,
Hu S
,
Schuetz EG
,
Lamba V
,
Messersmith WA
,
Wolff AC
,
Carducci MA
,
Sparreboom A
.
???displayArticle.abstract???
The purpose of this study was to evaluate the affinity of docetaxel for 14 transporter proteins and assess the functional significance of 17 variants in five genes involved in drug elimination. Among the transfected models investigated, OATP1B3 (SLCO1B3) was identified as the most efficient influx transporter for docetaxel. None of the observed genotypes (SLCO1B3, ABCB1, and ABCC2) was related with docetaxel clearance in 92 white patients (P > 0.17). However, the simultaneous presence of the CYP3A4*1B and CYP3A5*1A alleles was associated with a 64% increase in docetaxel clearance (P = 0.0015), independent of both sex and CYP3A activity (as determined using the erythromycin breath test). This haplotype was also associated with increased midazolam clearance in another population (P = 0.0198). An analysis of the CYP3A locus among CEPH-HapMap samples revealed that CYP3A4*1B is present exclusively among a subset of CYP3A5 expressors. Therefore, future studies should first stratify the population on the basis of CYP3A5 genotype and then compare CYP3A activity between individuals with and without the CYP3A4*1B allele.
Amirimani,
Increased transcriptional activity of the CYP3A4*1B promoter variant.
2003, Pubmed
Amirimani,
Increased transcriptional activity of the CYP3A4*1B promoter variant.
2003,
Pubmed
Ando,
Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
1999,
Pubmed
Baker,
Factors affecting cytochrome P-450 3A activity in cancer patients.
2004,
Pubmed
Baker,
Clinical pharmacokinetics of docetaxel : recent developments.
2006,
Pubmed
Baker,
Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry.
2004,
Pubmed
Bardelmeijer,
Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.
2002,
Pubmed
Bosch,
Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.
2006,
Pubmed
Bruno,
Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel.
2003,
Pubmed
Bruno,
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
1998,
Pubmed
Daly,
Significance of the minor cytochrome P450 3A isoforms.
2006,
Pubmed
de Jong,
Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.
2007,
Pubmed
Franke,
Influence of solute carriers on the pharmacokinetics of CYP3A4 probes.
2008,
Pubmed
Goh,
Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.
2002,
Pubmed
Hamzeiy,
Transcriptional regulation of cytochrome P4503A4 gene expression: effects of inherited mutations in the 5'-flanking region.
2003,
Pubmed
Hooker,
Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements.
2008,
Pubmed
Huisman,
MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid.
2005,
Pubmed
Joerger,
Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors.
2006,
Pubmed
Kloft,
Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs.
2006,
Pubmed
Kobayashi,
Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]).
2005,
Pubmed
,
Xenbase
Lagas,
Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.
2006,
Pubmed
Lepper,
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
2005,
Pubmed
Letschert,
Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8).
2004,
Pubmed
Lewis,
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.
2007,
Pubmed
Lin,
Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.
2002,
Pubmed
Marsh,
Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.
2007,
Pubmed
Messersmith,
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
2006,
Pubmed
Rau,
High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations.
2006,
Pubmed
Rodríguez-Antona,
Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles.
2005,
Pubmed
Schaid,
Caution on pedigree haplotype inference with software that assumes linkage equilibrium.
2002,
Pubmed
Shou,
Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver.
1998,
Pubmed
Sinibaldi,
Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma.
2006,
Pubmed
Sissung,
ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.
2008,
Pubmed
Smith,
Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination.
2005,
Pubmed
Smith,
Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel.
2005,
Pubmed
,
Xenbase
Smith,
Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics.
2007,
Pubmed
,
Xenbase
Sparreboom,
Pharmacogenomics of ABC transporters and its role in cancer chemotherapy.
2003,
Pubmed
Spurdle,
The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer.
2002,
Pubmed
ten Tije,
Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly.
2005,
Pubmed
Tran,
Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms.
2006,
Pubmed
van Herwaarden,
Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.
2007,
Pubmed
van Schaik,
CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians.
2000,
Pubmed
van Schaik,
CYP3A5 variant allele frequencies in Dutch Caucasians.
2002,
Pubmed
Veyrat-Follet,
Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization.
2000,
Pubmed
Wang,
Pharmacogenomics of sex difference in chemotherapeutic toxicity.
2007,
Pubmed
Wang,
Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 non-expressors.
2006,
Pubmed
Wojnowski,
Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
2002,
Pubmed
Xu,
Analyses of coding region polymorphisms in apical and basolateral human organic anion transporter (OAT) genes [OAT1 (NKT), OAT2, OAT3, OAT4, URAT (RST)].
2005,
Pubmed
Yamaguchi,
Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes.
2008,
Pubmed
